PORCUPINE: PORCN Inhibitor RXC004 Alone or in Combination with Nivolumab for Microsatellite Stable RNF43 or RSPO Altered Metastatic Colorectal Cancer

Condition: Colorectal Cancer

Sponsor: Redx Pharma Plc

Full Title
RXC004/0002: A Multi-arm, Phase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy of RXC004 in Monotherapy and in Combination with Nivolumab, in Patients with Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer who have Progressed following Therapy with Current Standard of Care

Study Treatment
Oral porcupine (PORCN) inhibitor RXC004 alone or in combination with nivolumab

Eligibility/Info
Microsatellite stable, stage IV, RNF43 or RSPO altered colorectal adenocarcinoma with progressive disease after treatment with a fluoropyrimidine, oxaliplatin, irinotecan, and anti-VEFGR or anti-EGFR (as indicated).

Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.